Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Letrozole 2.5 mg bioequivalence study versus Femara in healthy post-menopausal women
TCTR20260918008Phase 1Not yet recruiting
- Sponsor
- Dr. Sasitorn Kittivoravitkul
- Start
- Nov 2026
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of letrozole in breast cancer (2 arms), sponsored by Dr. Sasitorn Kittivoravitkul. Primary endpoints: Plasma letrozole concentration-time profile, Maximum plasma concentration (Cmax) and 2 more. Planned start Nov 2026; status: not yet recruiting.
02
Drugs
letrozole
03
Conditions
breast cancer
Beyond the preview
Go deeper on TCTR20260918008.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on TCTR20260918008.